Summit Therapeutics (SMMT) Tops Q4 EPS by 1c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.07), GBP0.01 better than the analyst estimate of (GBP0.08).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Iambic Therapeutics (IAM) files for proposed IPO
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
